Inhibits vitamin K epoxide reductase (VKOR) → depletes reduced vitamin K → prevents γ-carboxylation of factors II, VII, IX, X + proteins C/S. Narrow therapeutic index + massive interaction list + dietary K variability → DOACs (apixaban, rivaroxaban) now preferred for non-valvular indications.
Half-Life (t½)
PO: 40h
Dosing Guidelines
PO: Typical 4.67 mg (Range: 2–10 mg)
Target Organ Systems
immune-hematologic
Interactions
Vitamin K1 (major): Direct antagonism — consistent dietary K is the principle. [Holbrook 2005]